Ma Huangrong, Ma Lingyu, Yang Li, Cai Miaoying, Wang Yifu, Li Yue, Liang Chunyu, Xu Zhiyuan
Shenzhen University Medical School, Shenzhen University, Shenzhen, 518055, Guangdong, China.
Oncology Medical Center, The University of Hong Kong-Shenzhen Hospital, Shenzhen, 518000, Guangdong, China.
BMC Cancer. 2025 Feb 5;25(1):207. doi: 10.1186/s12885-025-13595-1.
This study aims to investigate the prognostic significance of dynamic hematological and clinical characteristics and to construct nomograms to predict overall survival (OS) in patients with cervical carcinoma who underwent radical radiotherapy.
The study analyzed patients with cervical cancer who underwent radical radiotherapy at The University of Hong Kong-Shenzhen Hospital between January 2015 and June 2022 and were staged as IB1 to IVA according to the International Federation of Gynecology and Obstetrics (FIGO) 2018 staging system. We identified predictive factors through univariate and multivariate cox regression analyses. Two multivariate analyses integrating different groups of variables were conducted independently. Concordance index (C-index), receiver operating characteristic (ROC), and Kaplan-Meier curves were used to evaluate the nomograms. Bootstrap validation was performed to determine the accuracy of the nomogram using 1000 resamples. The performances of proposed nomograms and FIGO 2018 staging system were compared to assess the prognostic value of hematological and inflammatory markers.
One hundred fifty-nine patients were included in this retrospective analysis. The median follow-up time was 41.37 months, and the 3-year OS rate was 82.6%. The first multivariate analysis of pre-treatment clinical factors and all hematological variables showed that FIGO2018 staging, and pre-treatment albumin levels were associated with 3-year OS. The final multivariate analysis incorporating all clinical factors, hematological variables, and inflammatory markers identified the following prognostic factors: FIGO2018 staging, rate of tumor shrinkage before brachytherapy, pre-treatment albumin levels, treatment times, minimum neutrophils during treatment, concurrent chemotherapy cycles, and lymphopenia grade. Calibration plots showed agreement between the OS predicted by the nomograms and actual OS. Kaplan-Meier curves demonstrated that patients in the high-risk group had shorter OS than those in the low-risk group (P ≤ 0.001). The C-index for the two nomograms was superior to that of the current FIGO2018 staging system, with values of 0.709 (95% Confidence Interval [CI], 0.622-0.795) and 0.803 (95% CI, 0.729-0.877), compared to 0.593 (95% CI, 0.508-0.678) for the FIGO system.
We developed and validated nomograms to predict OS in cervical cancer patients staged IB1 to IVA who underwent radical radiotherapy RT. The prognostic significance of dynamic changes in blood and inflammatory markers has been confirmed. The proposed nomogram exhibits robust predictive capabilities for estimating OS in these patients, facilitating risk stratification and individualized treatment.
本研究旨在探讨动态血液学和临床特征的预后意义,并构建列线图以预测接受根治性放疗的宫颈癌患者的总生存期(OS)。
本研究分析了2015年1月至2022年6月在香港大学深圳医院接受根治性放疗且根据国际妇产科联盟(FIGO)2018分期系统分期为IB1至IVA期的宫颈癌患者。我们通过单因素和多因素Cox回归分析确定预测因素。独立进行了两项整合不同变量组的多因素分析。使用一致性指数(C指数)、受试者工作特征(ROC)曲线和Kaplan-Meier曲线来评估列线图。进行Bootstrap验证以使用1000次重采样确定列线图的准确性。比较所提出的列线图和FIGO 2018分期系统的性能,以评估血液学和炎症标志物的预后价值。
本回顾性分析纳入了159例患者。中位随访时间为41.37个月,3年总生存率为82.6%。对治疗前临床因素和所有血液学变量的首次多因素分析表明,FIGO2018分期和治疗前白蛋白水平与3年总生存期相关。纳入所有临床因素、血液学变量和炎症标志物的最终多因素分析确定了以下预后因素:FIGO2018分期、近距离放疗前肿瘤缩小率、治疗前白蛋白水平、治疗次数、治疗期间最低中性粒细胞计数、同步化疗周期数和淋巴细胞减少分级。校准图显示列线图预测的总生存期与实际总生存期之间具有一致性。Kaplan-Meier曲线表明,高危组患者的总生存期短于低危组患者(P≤0.001)。两个列线图的C指数均优于当前的FIGO2018分期系统,分别为0.709(95%置信区间[CI],0.622 - 0.795)和0.803(95%CI,0.729 - 0.877),而FIGO系统的C指数为0.593(95%CI,0.508 - 0.678)。
我们开发并验证了列线图,以预测接受根治性放疗的IB1至IVA期宫颈癌患者的总生存期。血液和炎症标志物动态变化的预后意义已得到证实。所提出的列线图在估计这些患者的总生存期方面具有强大的预测能力,有助于风险分层和个体化治疗。